Hematologic Malignancies Market, By Type (Lymphoma, Leukemia, Multiple Myeloma), By Therapy (Radiotherapy, Chemotherapy, Immunotherapy), By End-Users (Hospitals, Homecare, Specialty Clinics, and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Report Code: PMI502322 | Publish Date: May 2023 | No. of Pages: 170

Hematologic Malignancies Market Overview

Hematologic Malignancies is the cancer which start begins in blood-forming tissues like in bone marrow or in immune system cells. Hematologic Malignancies are cancers which affect blood, lymph nodes and bone marrow. Hematologic cancer are Lymphoma, Leukemia, and Multiple Myeloma which are also called as blood cancer. Hematologic cancers are malignant disorders which are caused by uncontrolled division of abnormal cells, these abnormal cells arise from normal cells that undergone change, making them unable for responding to normal control mechanism that which limit their growth & division. Hematologic Malignancies is diagnosed by tissue biopsy, examination of blood smear, therapies, etc.  Anemia is caused by variety of mechanisms which includes neoplastic cell infiltration into bone marrow, nutritional deficiencies, & defects in erythropoiesis as result of cytotoxic therapy. Symptoms of malignancies are fatigue, change in weight an unintended loss or gain, lump or area of thickening that felt under skin, yellowing, darkening, redness, of skin, sores which didn’t heal, persistent cough, change in bowel, trouble in breathing, etc. Most common types of blood malignancies cancer are chronic lymphocytic leukemia, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, and multiple myeloma. Hematologic Malignancies are originates from uncontrolled growth of lymphoid tissues, and hematopoietic. Hematologic Malignancies are treated by chemotherapy, bone marrow transplantation, immunotherapy, and chimeric antigen receptor (CAR) T cell therapy. Bone marrow biopsy and endoscopic biopsy are diagnostic test used for confirmation of tumor if it is malignant or to determine the cause of infection and inflammation. Multiple myeloma is a rare disease and has become the second most common hematologic malignancy. Lymphoma, Leukemia, and Multiple Myeloma causes low hemoglobin. Malignancy can be cured if a person’s cancer is at earlier stage, and type of treatment they get. Breast cancer, lung cancer, prostate cancer, colorectal cancer are most common types of cancer. Most common type of anemia is seen in patient with hematological malignancies and cancer which results from underproduction of red cells i.e. hypo-proliferative anemia. Malignancies are hereditary and can be passed from parents to children. However, advancement in cancer therapies has enhanced the target market growth.

Attributes

Details

Hematologic Malignancies  Market Value (2022)

US$ 54.2Bn

Hematologic Malignancies  Market Projected Value (2032)

US$ 159.6Bn

Hematologic Malignancies  Market CAGR (2022 – 2032)

12.6%

Hematologic Malignancies Market Dynamics

        

                     Rising prevalence of blood cancer diseases and rate of urbanization

Rising prevalence of blood cancer diseases and rate of urbanization is one of the leading factors for the Hematologic Malignancies Market growth. Blood cancer is increasing due to radiation exposure, smoking, exposure to certain chemicals, etc.  Urbanization has caused change in diet. Eating processed, poor nutrition and unhealthy food affect the health causing implications in high incidence of cancers. Urbanization has given rise in smoking and alcohol intake which has become a fashion and has led to rise in cancer diseases. According to National report 2021 it was confirmed that incidence of blood cancer is continues to rise in Australia. In June 2021, The Australian Institute of Health and Welfare (AIHW) Cancer Data in Australia 2021 report confirmed that more than 50 Australians diagnosed with blood cancer every day this year and increase from 47 people daily in 2020.. For instance, in 2016, (NIH), the relationship between cancer incidence and urbanization in Iran were conducted by using Quantile Regression. Data obtained by Ministry of Health & Medical Education and relationship between urbanization and cancer morbidity was investigated by quantile regression and determined that lungs, pancreas, prostate, colorectal and breast cancers increasing with rate of urbanization. 90th percentile was maximum increase rate of breast cancer. 95th percentile was of prostate cancer, 75th percentile was of colorectal cancer, 95th percentile for lung cancer and 10th percentile for pancreas cancer. According to the results, it was determined that there was significant impact of rising urbanization on cancer morbidity due to risk factors like more pollution in urban areas, poor nutrition food, lack of exercise, smoking, alcohol intake, etc. According to data published by United Nations in 2018, about 55% of the world’s population resided in urban areas, and it is projected that this percentage will increase over the forecast period. However, the growth in blood cancer diseases and population in urban areas boosts the demand for Hematologic Malignancies Market.

Restrains:

Some chemo drugs may affect the normal cells in body which led to side effects like hair loss, loss of appetite, mouth sores, diarrhea or constipation, nausea and vomiting, etc. Some chemo drugs also affect the normal cells in bone marrow which lowers blood cell count which led to easy bleeding, increased risk of infections, fatigue and shortness of breath. However, costly medications and some side effects may somewhat restrain the target market growth.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Hematologic Malignancies Market Segmentation

The Hematologic Malignancies Market is segmented based on type, therapy, end-users, and region.

On the basis of Type, the Hematologic Malignancies Market is segmented into Lymphoma, Leukemia, Multiple Myeloma.  On the basis of Therapy, the target market is segmented into Radiotherapy, Chemotherapy, Immunotherapy. On the basis of End-Users, the target market is segmented into Hospitals, Homecare, Specialty Clinics, and others.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

On region the Hematologic Malignancies Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements. Moreover, rising prevalence of blood cancer diseases, robust healthcare infrastructure, presence of major key players, technological advancement, rising research & development activities, is anticipated to increase demand for Hematologic Malignancies in the region.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2022

Forecast period

2022 – 2032

Market representation

Revenue in USD Billion & CAGR from 2022 to 2032

Market Segmentation

By Type - Lymphoma, Leukemia, Multiple Myeloma

By Therapy – Radiotherapy, Chemotherapy, Immunotherapy

By End-Users - Hospitals, Homecare, Specialty Clinics, and others

 

 

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Hematologic Malignancies Market report based on type, therapy, end-users, and region:

Hematologic Malignancies Market, By Type:

  • Lymphoma
  • Leukemia
  • Multiple Myeloma

Hematologic Malignancies Market, By Therapy:

  • Radiotherapy
  • Chemotherapy
  • Immunotherapy

Hematologic Malignancies Market, By End-Users:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Hematologic Malignancies Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Hematologic Malignancies Market Key Players

The key players operating the Hematologic Malignancies Market includes, Johnson & Johnson Services Inc., Pfizer Inc., Novartis AG, AbbVie Inc., GlaxoSmithKline PLC., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals Inc., Celgene Corporation, F. Hoffman-La Roche Ltd., Takeda Pharmaceutical Company Limited., and others.

Recent Development:

  • In October 2022, Johnson & Johnson’s new blood cancer therapy is approved by U.S. FDA. Newly developed therapy teclistamab branded as ‘Tecvayli’ has been approved for treating adults with multiple myeloma. Newly developed ‘Tecvayli’ is a bispecific antibody that is engineered for redirecting body’s immune system for recognizing & killing cancer cells. Newly developed ‘Tecvayli’ is the first drug of its class which is approved for multiple myeloma.

Hematologic Malignancies Market Company Profile

  • Johnson & Johnson Services Inc.*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer Inc.
  • Novartis AG
  • AbbVie Inc.
  • GlaxoSmithKline PLC.
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals Inc.
  • Celgene Corporation
  • F. Hoffman-La Roche Ltd.
  • Takeda Pharmaceutical Company Limited.

 “*” marked represents similar segmentation in other categories in the respective section

Hematologic Malignancies Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for medical carts Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Type
      • Market Snippet, By Therapy
      • Market Snippet, By End-Users
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restrains
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Hematologic Malignancies Market, By Type
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Lymphoma
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Leukemia
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Multiple Myeloma
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  6. Hematologic Malignancies Market, By Therapy, 2022 – 2032, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Radiotherapy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Chemotherapy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Immunotherapy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  7. Hematologic Malignancies Market, By End-Users, 2022 – 2032, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Hospitals
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Homecare
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Specialty Clinics
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  8. Hematologic Malignancies Market, By Region, 2022 – 2032, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Therapy, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Therapy, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Therapy, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Therapy, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032

 

        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Therapy, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  2. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  3. Company Profiles
  • Johnson & Johnson Services Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • AbbVie Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • GlaxoSmithKline PLC.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Bristol-Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Glenmark Pharmaceuticals Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Celgene Corporation
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • F. Hoffman-La Roche Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Takeda Pharmaceutical Company Limited.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The Hematologic Malignancies Market is segmented into type, therapy, end-users, and region.

Hematologic Malignancies Market is driven by factors like rising prevalence of blood cancer diseases and rate of urbanization.

By region, the Hematologic Malignancies Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements.

The key players operating the Hematologic Malignancies Market includes, Johnson & Johnson Services Inc., Pfizer Inc., Novartis AG, AbbVie Inc., GlaxoSmithKline PLC., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals Inc., Celgene Corporation, F. Hoffman-La Roche Ltd., Takeda Pharmaceutical Company Limited., and others.